pre-IPO PHARMA
COMPANIES VC JOBS NEWS CONTACT

COMPANY OVERVIEW

Caelum Biosciences, Inc. (“Caelum”), a Fortress Biotech (NASDAQ:FBIO) Company, is a clinical-stage biotechnology company developing treatments for rare and life-threatening diseases.

LOCATION

  • New York, NY, USA

    • THERAPEUTIC AREAS

  • Rare Diseases

    • WEBSITE

    https://www.caelumbio.com/

    CAREER WEBSITE

    None

    SOCIAL MEDIA

    INVESTORS

    fortress-biotech

    PRESS RELEASES


    Oct 6, 2021

    Fortress Biotech Announces Closing of Acquisition of Caelum Biosciences by AstraZeneca


    Sep 29, 2021

    Fortress Biotech Announces Receipt of Notice of Option Exercise from AstraZeneca to Fully Acquire Caelum Biosciences, a Company Founded by Fortress Biotech


    Mar 1, 2021

    Caelum Biosciences Announces Collaborations with the Amyloidosis Advocacy Community and Support of Amyloidosis Awareness Month


    Jan 6, 2021

    AL Amyloidosis Market Insights, Epidemiology, and Market Report 2020 Featuring Janssen Pharmaceutical, Caelum Biosciences, Oncopeptides, Bristol-Myers Squibb, Acrotech Biopharma, and Sanofi


    Sep 14, 2020

    Alexion and Caelum Biosciences Announce Start of Phase 3 Studies of CAEL-101 in AL Amyloidosis


    For More Press Releases
    Google Analytics Alternative